Co-occurrence of Mayer-Rokitansky-Küster-Hauser syndrome and ovarian cancer: A case report and review of the literature

Roberta Villa, Jacopo Azzollini⁎, Bernard Peissel, Siranoush Manoukian

Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy

ARTICLE INFO

Keywords:
Mayer Rokitansky Küster Hauser syndrome
Low-grade serous carcinoma
Early onset ovarian cancer

ABSTRACT

Background: Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) is a congenital disorder of yet unknown etiology, characterized by agenesis/hypoplasia of the müllerian duct system. The occurrence of ovarian cancer (OC) in MRKHS is rare, with < 20 cases reported to date.

Case: A woman affected with MRKHS, developed an abdominal mass at the age of 33 years. Surgical examination revealed a blind vagina, small rudimentary uterus, two fully developed tubes and large bilateral ovarian tumors. The histological diagnosis was a low-grade serous carcinoma (LGSOC) of both ovaries, staged IIB. The patient showed a normal female karyotype and resulted negative at the BRCA1/2 genetic testing.

Conclusion: This is the first report of a LGSOC in a patient with MRKHS. Although the identification of familial cases with both MRKHS and OC raised the hypothesis of a common genetic origin, further data and reports of additional cases are needed in order to assess a possible association of the two conditions.

1. Introduction

Mayer-Rokitansky-Kuster-Hauser syndrome (MRKHS) is a Müllerian duct anomaly characterized by segmental or complete agenesis/hypoplasia of the upper vagina, uterus and, less frequently, fallopian tubes. Its prevalence worldwide is about 1:4500 live female births, representing one of the most frequent congenital malformations affecting the female genital tract and a common cause of primary amenorrhea. Malformations observed in MRKHS may be confined to the müllerian duct (MRKHS type 1 syndrome, Online Mendelian Inheritance in Man reference – OMIM %277000) or involve also other structures, including renal, skeletal, auditory and cardiac (MRKHS type 2 and Müllerian duct aplasia, Renal agenesis/ectopia, Cervical Somite dysplasia -MURCS, OMIM %601076).

The etiological basis of the syndrome is yet to be defined. Most cases are sporadic, though familial clustering has been reported, suggesting a putative genetic origin of the syndrome. However, data on genetic and genomic alterations identified in MRKHS patients, as well as the observed patterns of inheritance, are consistent with a polygenic/multifactorial disorder (Fontana et al., 2017).

In only a few MRKHS cases the occurrence of gynecological cancer was reported. Of particular interest was the report of Huepenbecker et al. describing two sisters affected with MRKHS, who also developed serous ovarian carcinoma (Huepenbecker et al., 2017). This finding raised the possibility of a shared genetic origin of the two conditions, although data concerning the association of ovarian cancer with MRKHS are still limited.

Herein we report an additional case of serous ovarian carcinoma occurring in a 33-year old woman affected with MRKHS.

2. Case

A 33-year-old Caucasian woman was referred to our Centre for the assessment of an abdominal mass. Due to primary amenorrhea, at the age of 14 years she underwent gynecological investigations revealing a blind vagina, small rudimentary uterus (3.91 × 1.13 cm), two fully developed tubes and normal ovaries, which led to the diagnosis of MRKHS syndrome. No additional malformations were detected at abdominal ultrasound (US) scan and spinal X-ray, with the exception of a slight s-shaped scoliosis. Karyotype analysis resulted normal (46,XX). Her past medical history was unremarkable for other medical conditions.

One month before being referred to our Centre, the patient had experienced abdominal pain and underwent a computed tomography scan revealing the presence of large bilateral ovarian masses with solid and cystic components. Transabdominal and transvaginal US were performed on admission, which showed bilateral adnexal masses with solid components, extending into the pelvis, and monolateral crescent...
Table 1
Cases of Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) patients affected with ovarian tumors.

| Article | Country     | MRKHS type | Ovarian tumor age at onset | Ovarian tumor histology | Ovarian tumor type | Ovarian tumor grade | Ovarian tumor stage (FIGO) |
|---------|-------------|------------|---------------------------|------------------------|--------------------|---------------------|--------------------------|
| (Ko et al., 2012) | Korea II | 37 | Germ cell | Serous carcinoma | II | III |
| (Juusela et al., 2017) | United States | 72 | Sex-cord stromal | Serous carcinoma | II | III |
| (Nusraft et al., 2016) | India | 65 | Epithelial | Endometrioid carcinoma | I | III |
| (Baes et al., 2013) | Korea II | 31 | Epithelial | Serous papillary<sup>a</sup> | III | |
| (Ko et al., 2012) | Korea II | 37 | Epithelial | Serous carcinoma | III | |
| (Javaliar et al., 2011) | Moldova na | 35 | Germ cell | Dysgerminoma | I | I |
| (Mishina et al., 2007) | Japan na | 8 | Germ cell | Yolk sac tumor<sup>3</sup> | I | I |
| (Takaeuchi et al., 2006) | Japan na | 64 | Epithelial | Serous carcinoma | I | III |
| (Takeuchi et al., 2006) | Japan na | 64 | Epithelial | Serous carcinoma | I | III |
| (Tsaur et al., 1995) | China | 4 | Germ cell | Immature teratoma | II | I |
| (Bae et al., 2013) | Korea II | 31 | Epithelial | Mixed epithelial carcinoma | III | |
| (Bae et al., 2013) | Korea II | 31 | Epithelial | Serous carcinoma | III | |
| (Juusela et al., 2017) | United States | 72 | Sex-cord stromal | Bilat. Sex-cord stromal tumor | na | I |
| (Hu Cao et al., 2017) | United States | na | Epithelial | Serous carcinoma | I | III |
| (Huepenbecker et al., 2017) | United States | 65 | Epithelial | Bilat. Sex-cord stromal tumor | I | II |
| (Koonings et al., 1991) | United States | I | 26 | Germ cell | Yolk sac tumor<sup>2</sup> | na | I |
| (Larsen et al., 1992) | Canada II | 34 | Sex-cord stromal | Sertoli cell<sup>2</sup> | II | I |
| (Pommerenke et al., 1994) | Germany II | 79 | Sex-cord stromal | Bilat. Sertoli cell | II | na |
| (Javaliar et al., 2011) | Germany II | 48 | Epithelial | Mixed epithelial carcinoma | III | |
| (Pommerenke et al., 1994) | Germany II | 79 | Sex-cord stromal | Bilat. Sertoli cell | II | na |

na, not available.

<sup>a</sup> Previous diagnosis of femur osteosarcoma at the age of 25, no chemotherapy or radiation therapy.

<sup>b</sup> Borderline tumor of the other ovary.

<sup>c</sup> Supernumerary ovary.

Red adrenal mass measured 65 × 58 × 74 mm, left mass measured 35 × 37 × 34 mm. A small uterus with no endometrial cavity was identified. A diagnosis of borderline ovarian tumor vs. carcinoma was suspected and a surgical approach was discussed with the patient.

Preoperative CA-125 level was elevated (3488 U/ml), other tumor markers (CEA, AFP, CA15.3, CA19.9) were in the normal range. Radical surgery with bilateral salpingo-oophorectomy, omentectomy and pelvic lymphadenectomy was performed. Surgical findings included multiple omental and peritoneal nodules, adnexal masses (max diameter: right 70 mm, left 40 mm) with papillary vegetations and uterine aplasia. Samples from peritoneal washing and multiple peritoneal biopsies were obtained. Hystopathological examination evidenced a low-grade serous carcinoma at both the ovaries, which was also localized at the anterior wall of the rectum; fallopian tubes showed no neoplastic invasion. Findings of the omental and peritoneal nodules included psammoma bodies and no evidence of cancer cells. No signs of residual disease were detected and the tumor was staged IB (FIGO). Postoperative recovery was unremarkable. The patient received six cycles of adjuvant chemotherapy with carboplatin.

Due to the personal history of early onset ovarian carcinoma, the patient was referred to genetic counseling. At pedigree evaluation, the patient's family history was not suggestive for any cancer predisposition syndrome (eg. Lynch syndrome). Both these patients resulted negative for pathogenic variants in BRCA1/2 genes was offered to the patient. The analysis resulted negative for germline variants, confirming the hypothesis of a different pathomechanism for LGSOC. Other genetic analyses were not considered because the patient's family history was not suggestive for any specific cancer predisposition syndrome (eg. Lynch syndrome).

In patients with MRKHS, OC is only occasionally described. To the best of our knowledge, only 14 cases have been reported worldwide: four from Europe, five from Asia and five from America. Information concerning patients affected with both MRKHS and OC are summarized in Table 1. Among all MRKHS patients with OC, eight (53%) developed an epithelial cancer, most of the serous type (5/8), four (27%) developed a germ cell tumor and three (20%) a sex-cord tumor. None of the previously reported patient developed a LGSOC. Median age at onset was 55 years (range 31–68) for epithelial tumors, 30 years (range 4–79) for non-epithelial tumors. Although the limited number of cases is not suitable for a statistical analysis, epithelial cancers appear to occur at a younger age in MRKHS patients compared with the general population. Of note, two additional patients from Korea were diagnosed before age 40 years. However, the OC described by Bae and colleagues (Bae et al., 2013), arose from a supernumerary pelvic ovary, which could be at higher risk for tumor development.

3. Discussion

Ovarian cancer (OC) is a common gynecological disease with > 230’000 new cases per year worldwide, accounting for about 3.5% of all newly diagnosed cancers. The estimated lifetime risk of developing OC is 1.3%, although incidence varies widely depending on both age and histological type.

> 90% of ovarian malignancies are of epithelial origin, which include five main histological subtypes: high-grade serous (HGSOC, ~70%), endometrioid (~10%), clear cell (~10%), mucinous (~3%) and low-grade serous (LGSOC, < 5%). Non-epithelial histologies, which account for about 10% of OCs, include sex-cord stromal tumor (~5%) and germ cell tumor (~2%). For all epithelial subtypes, incidence rates before ages 35–39 are very low. However, the incidence steadily increases with age, reaching the highest rate at 70–80 years. Notably, at ages younger than 30 years the incidence of other histotypes is higher than that of epithelial OC (Coburn et al., 2017).

According to these data, albeit OC is not a rare disease, our patient affected with LGSOC at the age of 33 years developed an infragroup tumor at an uncommon age. Due to the atypical presentation, a possible genetic predisposition was considered.

The main susceptibility genes associated with an increased risk of OC are BRCA1 and BRCA2, although pathogenic variants in these genes usually underlie the development of HGSCOT but not LGSOC. Despite the tumor histotype, due to the very early age at onset, genetic testing of the BRCA1/2 genes was offered to the patient. The analysis resulted negative for germline variants, confirming the hypothesis of a different pathomechanism for LGSOC. Other genetic analyses were not considered because the patient's family history was not suggestive for any specific cancer predisposition syndrome (eg. Lynch syndrome).

In patients with MRKHS, OC is only occasionally described. To the best of our knowledge, only 14 cases have been reported worldwide: four from Europe, five from Asia and five from America. Information concerning patients affected with both MRKHS and OC are summarized in Table 1. Among all MRKHS patients with OC, eight (53%) developed an epithelial cancer, most of the serous type (5/8), four (27%) developed a germ cell tumor and three (20%) a sex-cord tumor. None of the previously reported patient developed a LGSOC. Median age at onset was 55 years (range 31–68) for epithelial tumors, 30 years (range 4–79) for non-epithelial tumors. Although the limited number of cases is not suitable for a statistical analysis, epithelial cancers appear to occur at a younger age in MRKHS patients compared with the general population. Of note, two additional patients from Korea were diagnosed before age 40 years. However, the OC described by Bae and colleagues (Bae et al., 2013), arose from a supernumerary pelvic ovary, which could be at higher risk for tumor development.

Genetic testing in other cases was not performed, with the exception of the two sisters reported by Huepenbecker, who were affected with MRKHS and developed HGSCOT at the age of 63 and 64 years respectively. Both these patients resulted negative for pathogenic variants in BRCA1/2 and other 31 cancer susceptibility genes (Huepenbecker et al., 2017). Moreover, no data on cancer family history are available for
previously reported patients, therefore it is not possible to rule out that a putative cancer-predisposing syndrome might explain a subset of these cases.

4. Conclusions

In conclusion, we report on a new case of co-occurrence of MRKHS and OC and provide an updated review of the literature. To date, there is no evidence of an involvement of known cancer genes in MRKHS, as opposed to other genitourinary malformation syndromes, such as Denys-Drash syndrome (OMIM #194080) or WAGR (OMIM #194072), both characterized by a loss of function of the WT1 gene. Since the available data and knowledge about the etiopathological factors underlying the syndrome are still limited, it is not possible to define a putative correlation between MRKHS and increased risk for OC. The collection of further data and reports of additional cases will thus be crucial in order to either confirm or rule out a possible common pathomechanism underpinning MRKHS and OC.

4.1. Consent

Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Funding sources

The study was partially financed by funds from Italian citizens, who allocated the 5 × 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale dei Tumori according to the Italian laws (INT-Institutional strategic projects 5 × 1000), to S.M. allocated the 5 × 1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale dei Tumori according to the Italian laws (INT-Institutional strategic projects 5 × 1000), to S.M.

Author contribution

R.V. and J.A. revised the data and drafted the manuscript; B.P. and S.M. collected the clinical and genetic data and S.M. revised the manuscript.

Conflict of interest

The authors declare that they have no competing interests.

References

Bae, H., Ryu, M., Kim, I., Kim, S., Song, J., 2013. Cancer of the supernumerary ovary in Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. Oncol. Lett. 5 (3), 598–600. https://doi.org/10.3892/ol.2012.1073.

Coburn, S.B., Bray, F., Sherman, M.E., Trabert, B., 2017. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int. J. Cancer 140 (11), 2451–2460. https://doi.org/10.1002/ijc.30676.

Fontana, L., Gentilin, B., Fedele, L., Gervasi, C., Miozzo, M., 2017. Genetics of Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome. Clin. Genet. 91, 233–246. https://doi.org/10.1111/cge.12883.

Ghirardi, G., Magnani, A., 1995. Mayer-Rokitansky-Kuster-Hauser syndrome and ovarian cancer. Report of a case. Clin. Exp. Obstet. Gynecol. 22, 247–248 (PMID: 7554266).

Huepenbecker, S.P., Divine, L., Chu, C.S., Mutch, D.G., 2017. Two sisters with Mayer-Rokitansky-Küster-Hauser syndrome and serous adenocarcinoma of the ovary. Gynecol. Oncol. Rep. 22, 13–15. https://doi.org/10.1016/j.gyore.2017.09.002.

Juusela, A., Naghi, L., Thani, S., 2017. Mayer-Rokitansky-Küster-Hauser syndrome with bilateral ovarian Sertoli cell tumors: review of the literature and report of a rare case. Female Pelvic Med. Reconstr. Surg. 24 (5), e32–e34. https://doi.org/10.1097/SPV.0000000000000483.

Kavalars, A., Saït, K., Marar, E., Shakra, R., Diedrich, K., 2011. Ovarian cancer and Mayer-Rokitansky-Kuster-Hauser syndrome. Gynecol. Surg. 8 (2), 197–199. https://doi.org/10.1007/s10397-009-0488-0.

Ko, A.R., Kim, J.H., Park, S.Y., Jeon, Y.E., Kim, S.J., Rhim, C.C., Kang, J.B., Park, Y.H., 2012 Dec. A case of ovarian cancer developed in Mayer-Rokitansky-Küster-Hauser syndrome: innate carcinogenesis of ovarian cancer. Korean J. Obstet. Gynecol. 55 (12), 1001–1005. https://doi.org/10.5468/KJOG.2012.55.12.1001.

Koonings, P.P., al-Maryati, L., Schlaerth, J.B., Lobo, R.A., 1991. Mayer-Rokitansky-Kuster-Hauser syndrome: innate carcinogenesis of ovarian cancer. Fertil. Steril. 56, 577–578. 1894040.

Larsen, E.T., Chang-Poon, V., Benediktsson, H., Robertson, D.L., Stuart, G.C.E., 1992. Bilateral ovarian tumors in a woman with Mayer-Rokitansky-Kuster-Hauser syndrome. Adolesc. Pediatr. Gynecol. 5 (3), 198–200. https://doi.org/10.1016/S0932-8610(12)80029-6.

Mishina, A., Gladun, E., Petrovici, V., Iakovleva, I., 2007. Ovarian dysgerminoma in Mayer-Rokitansky-Kuster-Hauser syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 131 (1), 105–106. https://doi.org/10.1016/j.ejogrb.2006.02.007.

Nusrath, S., Goel, V., Varma, P., Pawar, S., Murthy, S., Raju, K., 2016. Ovarian cancer and Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a rare combination. Indian J. Gynecol. Oncolog. 14 (2), 30. https://doi.org/10.1007/s40944-016-0059-z.

Pommerenke, F., Tesmann, D., Meyer, K., 1994. Giant Sertoli cell tumor cell of the ovary in Mayer-Rokitansky-Küster-Hauser syndrome. Zentralbl. Gynakol. 116 (5), 295–300 (PMID: 8023628).

Takeuchi, K., Oomori, S., Oda, N., Maeda, K., Kaji, Y., Maru, T., 2006. Coexistence of Mayer-Rokitansky-Küster-Hauser syndrome and yolk sac tumor of the ovary in a prepubertal girl. Acta Obstet. Gynecol. Scand. 85 (2), 245–247 (PMID: 16532924).

Tsaur, G., Lee, M., Su, S., Wu, M., Huang, T., 1995. Mayer-Rokitansky-Kuster-Hauser syndrome with immature teratoma of the ovary at age 4 years. Gynecol. Oncol. 56 (3), 456–459. https://doi.org/10.1006/gyno.1995.1082.